When was Biotheus founded?

Biotheus was founded in 2018 and raised its 1st funding round within a year of its incorporation.

Where is Biotheus located?

Biotheus is headquartered in Zhuhai, China.

Who is the current CEO of Biotheus?

Xiaolin Liu of Biotheus. They have also founded 1 company.

How many employees does Biotheus have?

As of Mar 01, 2026, the latest employee count at Biotheus is 10 - 49.

Is Biotheus a funded company?

Biotheus is a funded company, having raised a total of $14.5M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2018.

When was the latest funding round of Biotheus?

Biotheus' latest funding was a $***** Seed round on Mar 02, 2021, with participation from 9 investors. Its primary sector is Oncology. In China, the Oncology sector has seen $765M in funding in 2026 to date.

Where does Biotheus rank among its competitors?

Biotheus ranks 865th amongst 3289 active competitors, of which 1119 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Biotheus?

Biotheus' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Immuneel secured the most recent funding round in June, 2026.

Biotheus - 2026 Company Profile, Team, Funding & Competitors

Q: Is Biotheus an acquired company?

Biotheus got acquired by BioNTech on Nov 13, 2024.

Biotheus is an acquired company based in Zhuhai (China), founded in 2018 by Xiaolin Liu. It operates as a Developer of antibody-based therapeutics for cancer treatment. Biotheus has raised $14.5M in funding from investors like General Atlantic, New Alliance Capital and IDG Capital. The company has 3289 active competitors, including 1119 funded and 775 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of antibody-based therapeutics for cancer treatment. The company's candidates include PM8001, PM8003, PM1003, PM 1008, PM 1011, and PM1016 for cancer treatment.

Key Metrics

Founded Year

2018

Location

Zhuhai, China

Stage

Acquired

Total Funding

$14.5M in 4 rounds

Latest Funding Round

Seed, Mar 02, 2021, $*****

Investors

General Atlantic & 9 more

Ranked

865^th among 3289 active competitors

Employee Count

10 - 49 as on Mar 01, 2026

Similar Companies

Jazz Pharmaceuticals & 2981 more

Exit Details

Acquired by BioNTech (Nov 13, 2024)

View Biotheus' full profile

Biotheus got acquired by BioNTech on Nov 13, 2024 at an acquisition amount of $*****.

Click here to take a look at Biotheus's acquisition in detail

Biotheus has raised a total funding of $14.5M over 4 rounds. Its first funding round was on 2018. Its latest funding round was a Seed round on Mar 02, 2021 for $*****. 9 investors participated in its latest round. Biotheus has 10 institutional investors.

Here is the list of recent funding rounds of Biotheus:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 02, 2021	4547370	Seed	9973273	7489038	4131146	2769096
Jun 2020	6436290	Seed	5194850	3147352	4231151	8725223
Jun 26, 2019	1385155	Seed	7253200	7891271	Shiyu	3466610

Access funding benchmarks and valuations. Sign up today!

View details of Biotheus's funding rounds and investors

The founders of Biotheus is Xiaolin Liu. Xiaolin Liu is the CEO of Biotheus.

Here are the details of Biotheus' key team members:

Xiaolin Liu: Co-Founder & CEO of Biotheus.

View details of Biotheus's Founder profiles and Board Members

Biotheus' employee count trend

Biotheus has 10 - 49 employees as of Mar 26. Here is Biotheus's employee count trend over the years:

Uncover Biotheus' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Biotheus include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Biotheus, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Domain Associates, Fidelity Investments & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
865th	Biotheus 2018, Zhuhai (China), Acquired	Developer of antibody-based therapeutics for cancer treatment	$14.5M	IDG Capital, General Atlantic & 8 others	43/100